At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 955 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
In Brief
A Phase 3 clinical trial evaluating Erenumab and Placebo for Migraine. Completed, enrolled 955 participants across 129 sites in 13 countries.
Detailed Summary
The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesAustria, Belgium, Canada, Czechia, Finland, Germany, Netherlands, Poland, Slovakia, Sweden, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartJul 2015
Primary CompletionSep 2016
Study CompletionJun 2017
TodayJul 2026
First PostedMay 28, 2015
Enrollment StartJul 17, 2015
Primary CompletionSep 5, 2016
Study CompletionJun 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.1 years ago
Interventions
Erenumabdrug
Administered by subcutaneous injection once a month
Placebodrug
Administered by subcutaneous injection once a month